Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Accumulated Expenses (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Other Accumulated Expenses for 7 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 32.83% to $26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.5 million through Dec 2025, up 32.83% year-over-year, with the annual reading at $26.5 million for FY2025, 32.83% up from the prior year.
  • Other Accumulated Expenses hit $26.5 million in Q4 2025 for IDEAYA Biosciences, up from $628000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $28.1 million in Q2 2025 to a low of $92000.0 in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $10.3 million across 5 years, with a median of $9.2 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: surged 25486.21% in 2021 and later plummeted 98.54% in 2024.
  • Year by year, Other Accumulated Expenses stood at $7.4 million in 2021, then tumbled by 98.76% to $92000.0 in 2022, then skyrocketed by 11504.35% to $10.7 million in 2023, then skyrocketed by 86.92% to $20.0 million in 2024, then soared by 32.83% to $26.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for IDYA at $26.5 million in Q4 2025, $628000.0 in Q3 2025, and $28.1 million in Q2 2025.